Alecensa (alectinib) demonstrated a 22% reduction in the risk of death compared with Xalkori (crizotinib) in the frontline ...

Zipalertinib shows 31% intracranial response and good tolerability in CNS-involved EGFR-mutated lung cancer, data presented at ESMO 2025.

TTFields treatment following stereotactic radiosurgery prolonged the time to intracranial progression for patients with brain metastases from NSCLC.

Among patients with operable, newly diagnosed brain metastases, treatment with GammaTile was associated with a greater than ...

Researchers review melanoma subtypes, focusing on therapeutic advances in metastatic ocular melanoma, including TILs, ImmTACs, and targeted therapies.

BERLIN -- Almost half of patients with advanced ALK -positive non-small cell lung cancer (NSCLC) have lived 7 years or longer ...

Cancer researchers have completed one of the most comprehensive studies of the cells inside melanoma brain metastases. Brain metastasis is one of the most common causes of cancer-related deaths and ...

Patients enrolled had NET liver metastases of any grade or origin that were progressive, symptomatic, or represented a high ...

Advanced colon cancer is the leading cause of cancer-related death in young American men and the second highest worldwide. In the majority of these patients, as the cancer advances it metastasizes to ...

The survival of patients with metastases is variable ranging from a matter of months to many years. The ability to predict prognosis and response to treatment has a considerable impact on patient ...

A study suggests a new approach, or, possibly two new approaches against prostate cancer bone metastases: While targeted therapies and anti-cancer immunotherapies have not been especially successful ...